Cargando…
First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects
We assessed the pharmacokinetics and safety of a single oral administration of selatinib to healthy Chinese subjects and evaluated the potential bioavailability advantage of selatinib relative to lapatinib. Healthy subjects aged 18–40 years were enrolled in this two-part study: Part 1, a single asce...
Autores principales: | Wang, Meng-na, Kuang, Yun, Gong, Li-ying, Hua, Ye, Pei, Qi, Guo, Cheng-xian, Cao, Yu, Huang, Jie, Yang, Guo-ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575490/ https://www.ncbi.nlm.nih.gov/pubmed/32535812 http://dx.doi.org/10.1007/s10637-020-00959-6 |
Ejemplares similares
-
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses
por: Uhl, Wolfgang, et al.
Publicado: (2013) -
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013) -
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
por: Harding, James J., et al.
Publicado: (2018) -
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010) -
Pharmacokinetic study of aldoxorubicin in patients with solid tumors
por: Mita, Monica M., et al.
Publicado: (2014)